Tag Archive for: vascular diseases

Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial

/in

Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment Primary endpoint met with standout sustained patency rates, with major improvements demonstrated across the board compared to standard of care Enhances clinical profile of aXess, reinforcing excellent first-in-human outcomes amid ongoing US pivotal trial and ahead of commercialization EINDHOVEN, The Netherlands, 24 […]

Read more

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

/in

Enrolment completed – 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026 Capability to obtain market approval is further strengthened with the appointment of Rob Eyers as Chief Technology Officer. EINDHOVEN, The Netherlands, 7 January 2025 – Xeltis, a leading […]

Read more

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development

/in

Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership team following IDE approval for initiation of US pivotal study for aXessTM, its restorative vascular access conduit EINDHOVEN, The Netherlands, 5 November 2024 – Xeltis, a leading developer of transformative implants that enable the natural […]

Read more

Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium

/in

Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who need vascular access to hemodialysis aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, long-term living vessel EINDHOVEN, The Netherlands, 17 April 2024 – Xeltis, […]

Read more

Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi

/in

Neuraxpharm, the central nervous system (CNS) specialist, to acquire two portfolios of established products for CNS disorders, pain and vascular diseases Dusseldorf and Barcelona, July 12, 2022 – Neuraxpharm Group (“Neuraxpharm”) today announced that it has entered into a definitive agreement to acquire two product portfolios for CNS disorders, pain and vascular diseases from Sanofi. With […]

Read more